What Causes PCOS? A Clinical Guide to Polycystic Ovary Syndrome

By
Published Updated Last reviewed
Clinical medical image for diabetes faq: What Causes PCOS? A Clinical Guide to Polycystic Ovary Syndrome

At a glance

  • Prevalence / 8 to 13% of reproductive-age women worldwide (WHO estimate)
  • Primary hormonal driver / excess androgens (testosterone, DHEA-S) produced by the ovaries and adrenal glands
  • Metabolic hallmark / insulin resistance present in approximately 70% of people with PCOS
  • Genetic risk / first-degree relatives of someone with PCOS have a 20 to 40% higher chance of developing it
  • Diagnostic standard / Rotterdam criteria (2003): 2 of 3 features required (irregular ovulation, hyperandrogenism, polycystic ovarian morphology)
  • Most underdiagnosed group / lean individuals with PCOS, who may lack visible metabolic signs
  • Associated long-term risks / type 2 diabetes, endometrial cancer, cardiovascular disease, depression
  • Key treatment targets / insulin sensitization, androgen suppression, cycle regulation
  • Average diagnosis delay / 2 years from first symptom presentation
  • Guideline source / 2023 International Evidence-Based Guideline for PCOS (Monash University)

The Core Question: Why Does PCOS Happen?

PCOS does not have a single on/off cause. It arises from several biological systems malfunctioning in parallel, with each person's presentation shaped by which system fails most prominently. The three main biological drivers are abnormal insulin signaling, excess androgen production, and a disrupted feedback loop between the brain and the ovaries.

These three processes reinforce one another. Insulin resistance causes the pancreas to secrete more insulin, and high insulin tells the ovaries to make more testosterone. Extra testosterone disrupts the normal hormonal signal that tells a follicle to fully mature and release an egg. The follicle stalls, and the cycle becomes irregular or stops entirely.

Why "Polycystic" Is a Misleading Name

The term "polycystic" suggests that cysts are the defining feature. They are not. What appear as cysts on ultrasound are actually small follicles that stalled before reaching full maturity. The 2023 International Evidence-Based Guideline for Assessment and Management of PCOS specifically states that polycystic ovarian morphology alone is not sufficient for diagnosis, and many people with PCOS do not show it at all on imaging.

The Three-System Breakdown

Think of PCOS as a traffic jam involving three connected roads:

  • Road 1 (Insulin signaling): cells do not respond normally to insulin, so the pancreas floods the bloodstream with more of it
  • Road 2 (Androgen production): high insulin directly stimulates ovarian theca cells to produce testosterone at abnormally high rates
  • Road 3 (HPO axis): elevated androgens distort the pulsatile release of GnRH from the hypothalamus, skewing the LH-to-FSH ratio and preventing normal follicle maturation

Any one of these failures can start the cascade. Genetics, diet, body weight, and chronic low-grade inflammation all influence which road breaks down first.

Insulin Resistance and Hyperinsulinemia

Insulin resistance is the most clinically actionable cause of PCOS. Approximately 70% of women with PCOS have measurable insulin resistance, even those at a normal body weight, according to data published in Endocrine Reviews.

When cells resist insulin's signal, the pancreas compensates by secreting more insulin. Chronically elevated insulin (hyperinsulinemia) has a direct effect on the ovary: it binds to IGF-1 receptors on theca cells and amplifies the response to LH, causing those cells to produce far more androgen than the ovary needs.

How Insulin Resistance Is Measured in PCOS

Standard fasting glucose tests often miss insulin resistance in younger people. More sensitive measures include:

  • HOMA-IR (fasting insulin x fasting glucose / 405): a HOMA-IR above 2.0 suggests insulin resistance in most clinical contexts
  • Fasting insulin alone: values above 15 mIU/L in the fasting state are associated with ovulatory dysfunction in PCOS populations
  • Oral glucose tolerance test (OGTT): the American Diabetes Association recommends an OGTT for all people with PCOS due to elevated type 2 diabetes risk

Lean PCOS and Insulin Resistance

Lean individuals with PCOS (BMI <25) can still have significant insulin resistance. A 2012 study in the Journal of Clinical Endocrinology and Metabolism found that lean women with PCOS showed impaired insulin-stimulated glucose disposal comparable to that seen in obese women with PCOS. Body weight alone does not determine metabolic risk.

Androgen Excess: The Hormonal Driver of Symptoms

Hyperandrogenism, meaning elevated androgens or clinical signs of androgen excess, is the single feature most consistently linked to PCOS across all diagnostic frameworks. The Endocrine Society's 2013 Clinical Practice Guideline on PCOS describes hyperandrogenism as "the key feature" of the syndrome.

Androgens involved include:

  • Free testosterone: the biologically active fraction, often elevated even when total testosterone is within range
  • DHEA-S: an androgen primarily produced by the adrenal glands, elevated in roughly 25% of PCOS cases
  • Androstenedione: a precursor to testosterone, often elevated in PCOS and measurable on standard panels

Where the Extra Androgens Come From

The ovary accounts for the majority of excess androgen in most PCOS cases. Theca cells in the ovarian follicle wall are stimulated by LH and, in the presence of hyperinsulinemia, produce testosterone at rates that exceed normal physiologic need. The enzyme CYP17A1, which catalyzes androgen synthesis, shows intrinsically higher activity in the theca cells of people with PCOS, a finding reported in a 1997 paper in the New England Journal of Medicine.

The adrenal gland contributes in a subset of patients. Adrenal androgen excess is more common in people with a higher DHEA-S and may reflect heightened adrenal sensitivity to ACTH rather than a separate disease process.

What High Androgens Do to the Body

Symptoms driven by androgen excess:

  • Hirsutism: coarse terminal hair on the face, chest, abdomen, or back (reported by 60 to 70% of those with PCOS)
  • Acne: particularly cystic or jaw-line acne that does not respond to standard topical treatment
  • Androgenic alopecia: thinning at the crown or temples, following a male-pattern distribution
  • Anovulation: high androgens disrupt the mid-cycle LH surge, preventing ovulation

These symptoms are not purely cosmetic. They are clinical biomarkers of an underlying hormonal imbalance that carries long-term metabolic consequences.

The Hypothalamic-Pituitary-Ovarian Axis Dysfunction

The HPO axis is the hormonal communication network that coordinates the menstrual cycle. The hypothalamus releases GnRH in pulses; the pituitary responds by secreting LH and FSH; the ovary responds by maturing follicles and releasing eggs. In PCOS, this system is out of rhythm.

Abnormal GnRH Pulsatility

GnRH is normally secreted in pulses roughly every 60 to 90 minutes in the follicular phase of the cycle. In PCOS, pulse frequency accelerates. Faster GnRH pulses preferentially stimulate LH secretion while suppressing FSH. The net result is an elevated LH-to-FSH ratio (often 2:1 or higher, compared with the normal near-1:1 ratio in the early follicular phase).

High LH without adequate FSH means follicles begin to develop but cannot complete maturation. They stall at a small antral size, accumulate in the ovary (producing the polycystic appearance on ultrasound), and produce more androgens under LH stimulation rather than completing ovulation.

Progesterone Resistance in the Hypothalamus

Normally, progesterone slows GnRH pulse frequency during the luteal phase, giving the system a rest. In PCOS, the hypothalamus shows reduced sensitivity to progesterone's inhibitory effect. This means the braking signal does not work properly, and GnRH keeps pulsing too fast even after ovulation would have occurred. Research published in The Journal of Clinical Investigation identified this progesterone resistance in GnRH neurons as a probable primary defect in PCOS, not purely a secondary consequence of high androgens.

Genetic Contributions to PCOS

PCOS clusters in families. A woman with a mother or sister diagnosed with PCOS has a 20 to 40% higher absolute risk of developing the condition herself, based on family study data reviewed by the National Institutes of Health.

No single "PCOS gene" has been identified. The condition appears polygenic, with genome-wide association studies (GWAS) identifying over 20 loci associated with PCOS risk. Key candidate genes include:

  • FSHR (FSH receptor): variants affect ovarian sensitivity to FSH signaling
  • LHCGR (LH/hCG receptor): variants alter the ovary's response to LH
  • CYP11A1 and CYP17A1: genes controlling steroidogenesis; variants linked to androgen overproduction
  • INSR (insulin receptor): variants associated with post-receptor insulin signaling defects specific to PCOS

A 2019 GWAS published in Nature Medicine (N=10,074 cases, 103,164 controls) identified genetic associations near genes involved in both gonadotropin signaling and metabolic regulation, suggesting that the reproductive and metabolic features of PCOS may share a common genetic origin rather than one causing the other.

Inflammation and Environmental Triggers

Chronic low-grade inflammation is present in PCOS independent of obesity. C-reactive protein (CRP), TNF-alpha, and interleukin-18 are consistently elevated in PCOS populations. A meta-analysis in the European Journal of Endocrinology (43 studies) confirmed that CRP is significantly higher in women with PCOS compared with BMI-matched controls (P<0.001).

How Inflammation Worsens PCOS

Inflammatory cytokines interfere with insulin receptor signaling at the cellular level, directly worsening insulin resistance. They also stimulate adrenal and ovarian androgen production. This creates a feedback loop: PCOS produces inflammation, and inflammation makes PCOS worse.

Environmental and Lifestyle Factors

Genetics loads the gun, but environment pulls the trigger in many cases. Factors that may worsen underlying PCOS predisposition include:

  • Excess adipose tissue: fat cells, particularly visceral fat, secrete inflammatory cytokines and contribute to insulin resistance. Each 1 kg/m² increase in BMI is associated with a measurable increase in androgen levels in susceptible individuals.
  • Endocrine-disrupting chemicals (EDCs): bisphenol A (BPA) exposure has been associated with higher androgen levels in women with PCOS. A study in the Journal of Clinical Endocrinology and Metabolism found serum BPA was significantly higher in women with PCOS than in controls (P<0.05).
  • Sleep disruption: obstructive sleep apnea affects up to 35% of people with PCOS and independently worsens insulin resistance.
  • Prenatal androgen exposure: daughters of women with PCOS show higher AMH levels and more irregular cycles in adolescence, suggesting that in-utero androgen exposure may program HPO axis dysfunction before birth.

How PCOS Is Diagnosed

The most widely used diagnostic framework remains the Rotterdam criteria, established in 2003 and reaffirmed in the 2023 International PCOS Guideline. A diagnosis requires at least 2 of the following 3 features:

  1. Irregular or absent ovulation (cycles <21 days or >35 days, or fewer than 8 cycles per year)
  2. Clinical or biochemical hyperandrogenism (hirsutism, acne, alopecia, or elevated free/total testosterone)
  3. Polycystic ovarian morphology on ultrasound (20 or more follicles in either ovary, or ovarian volume >10 mL)

Other causes must be excluded before confirming PCOS: congenital adrenal hyperplasia, hyperprolactinemia, Cushing syndrome, and thyroid dysfunction all produce overlapping symptoms.

Recommended Lab Panel at Initial Evaluation

A thorough first-visit workup should include:

  • Total and free testosterone, DHEA-S, androstenedione
  • LH, FSH (drawn cycle days 2 to 5 if cycles are present)
  • Fasting glucose and insulin (calculate HOMA-IR)
  • Two-hour OGTT if fasting glucose is borderline
  • TSH and prolactin (to exclude mimics)
  • AMH (anti-Mullerian hormone), which is typically elevated in PCOS and may eventually replace the ultrasound criterion
  • Lipid panel (cardiovascular risk screening)

The Endocrine Society guideline explicitly recommends screening all people with PCOS for metabolic syndrome, with repeat screening every 1 to 3 years even if initial values are normal.

Long-Term Health Risks Linked to PCOS Causes

Because the underlying causes of PCOS (insulin resistance, hyperandrogenism, and chronic inflammation) affect multiple organ systems, the condition carries risks that extend well beyond reproductive health.

Metabolic and Cardiovascular Risk

People with PCOS have a 3-fold higher risk of developing type 2 diabetes compared with age-matched controls, per a cohort study in Diabetes Care (N=8,607, 11-year follow-up). The risk persists after adjusting for BMI, confirming that metabolic susceptibility is intrinsic to PCOS rather than purely a consequence of weight.

Cardiovascular disease markers including carotid intima-media thickness, impaired endothelial function, and dyslipidemia are already measurable in reproductive-age women with PCOS, as documented in a 2015 review in the Journal of the American College of Cardiology.

Endometrial Cancer Risk

Anovulation means the uterine lining is exposed to unopposed estrogen without the protective monthly shedding triggered by progesterone. Women with PCOS have approximately a 2.7-fold higher risk of endometrial cancer, per a systematic review in Fertility and Sterility. Regular cycle regulation, whether through progestin therapy, combined hormonal contraceptives, or ovulation induction, reduces this risk.

Mental Health

Rates of depression and anxiety are approximately 2 to 3 times higher in people with PCOS than in the general population. A 2018 meta-analysis in Human Reproduction found a pooled prevalence of depression of 36% and anxiety of 41% among PCOS patients. Androgen levels, body image concerns, infertility stress, and the burden of a chronic condition all contribute.

Treatment Approaches Targeting Root Causes

Treatment in PCOS is matched to the predominant underlying mechanism in each person.

Addressing Insulin Resistance

  • Metformin 500 to 2,000 mg/day: reduces hepatic glucose output, lowers insulin, and modestly lowers androgen levels. A Cochrane review (Cochrane Database 2012) found metformin improved ovulation rates significantly compared with placebo (OR 3.88, P<0.001).
  • Weight loss (5 to 10% of body weight): restores ovulation in a meaningful proportion of anovulatory women with PCOS. Even modest weight reduction lowers fasting insulin and free testosterone within 8 to 12 weeks.
  • GLP-1 receptor agonists: agents like semaglutide (Ozempic/Wegovy) and liraglutide are being studied specifically in PCOS. A 2022 randomized trial in Diabetes, Obesity and Metabolism found liraglutide 1.8 mg daily over 12 weeks reduced free testosterone by 22% and improved menstrual regularity in overweight women with PCOS.

Reducing Androgen Excess

  • Combined oral contraceptives (COCs): suppress LH-driven androgen production from the ovary and increase sex-hormone-binding globulin (SHBG), which binds free testosterone. COCs remain first-line for hirsutism management per Endocrine Society guidelines.
  • Spironolactone 50 to 200 mg/day: an androgen receptor blocker that reduces hirsutism and acne. Requires reliable contraception due to teratogenic risk in male fetuses.
  • Finasteride 2.5 to 5 mg/day: a 5-alpha-reductase inhibitor sometimes used for androgenic alopecia in PCOS; also requires contraception.

Restoring Ovulation for Fertility

  • Letrozole (aromatase inhibitor): now the preferred first-line ovulation induction agent for PCOS, replacing clomiphene. The PCOSACT trial (NEJM 2014, N=750) found letrozole produced higher live birth rates than clomiphene (27.5% vs. 19.1%, P<0.001).
  • Inositol (myo-inositol and D-chiro-inositol): insulin sensitizers with modest ovulation-restoring effects; evidence supports use as an adjunct, not a standalone therapy.

Frequently asked questions

›What is the main cause of PCOS?
No single cause explains every case. The main biological drivers are insulin resistance leading to hyperinsulinemia, excess androgen production by the ovaries and adrenal glands, and abnormal signaling from the hypothalamic-pituitary-ovarian axis. Genetics create susceptibility, and factors like excess body weight, inflammation, and certain chemical exposures can trigger or worsen the condition in predisposed individuals.
›Is PCOS caused by too much testosterone?
Elevated androgens, including testosterone, are a central feature of PCOS, but the excess testosterone is itself a consequence of deeper problems: high insulin stimulating ovarian theca cells and an LH-to-FSH imbalance that drives androgen production. So PCOS causes high testosterone rather than the reverse, though once elevated, testosterone worsens the hormonal cycle by further disrupting ovulation.
›Can you get PCOS if you are lean?
Yes. Lean individuals (BMI <25) account for roughly 20 to 30% of all PCOS cases. Lean PCOS still involves insulin resistance, hyperandrogenism, and HPO axis disruption. Because visible metabolic signs are absent, lean PCOS is frequently missed or delayed in diagnosis by an average of two or more years.
›Is PCOS genetic or caused by lifestyle?
Both contribute. PCOS is polygenic, meaning multiple genes each add a small amount of risk, and first-degree relatives of people with PCOS have a 20 to 40% higher absolute risk. Lifestyle factors, particularly excess caloric intake, physical inactivity, poor sleep, and exposure to endocrine-disrupting chemicals, can activate or worsen genetic susceptibility without being the sole cause.
›Does PCOS get worse with age?
PCOS changes with age rather than simply worsening. Androgen levels naturally decline after the mid-30s, so hirsutism and acne may improve. Menstrual irregularity can also improve somewhat near perimenopause. The metabolic risks, including insulin resistance, type 2 diabetes, and cardiovascular disease risk, tend to increase with age and remain even after menopause.
›Can stress cause PCOS?
Stress does not directly cause PCOS, but chronic stress elevates cortisol, which stimulates adrenal androgen production and worsens insulin resistance. In someone already genetically predisposed, prolonged stress could push a borderline hormonal picture into a clinically diagnosable one. Stress management is therefore a reasonable adjunct to medical treatment, not a replacement.
›How does PCOS affect fertility?
PCOS is the most common cause of anovulatory infertility, accounting for roughly 80% of cases. Without regular ovulation, conception requires intervention. Letrozole is the preferred first-line agent (live birth rate 27.5% per cycle in the PCOSACT trial vs. 19.1% with clomiphene). Most people with PCOS can conceive with appropriate treatment.
›What hormones are abnormal in PCOS?
The most consistently abnormal hormones are elevated free testosterone, elevated DHEA-S (in about 25% of cases), elevated LH with a high LH-to-FSH ratio (often 2:1 or higher), elevated fasting insulin, and elevated AMH (anti-Mullerian hormone). Estrogen itself is often normal in absolute terms but exerts a prolonged unopposed effect due to lack of progesterone from anovulation.
›What is the Rotterdam criteria for PCOS diagnosis?
The Rotterdam criteria (2003) require 2 of the following 3 features: (1) irregular or absent ovulation (cycles shorter than 21 days or longer than 35 days), (2) clinical or biochemical signs of excess androgens (hirsutism, acne, elevated testosterone), and (3) polycystic ovarian morphology on ultrasound (20 or more small follicles or ovarian volume above 10 mL). Other hormonal conditions that mimic PCOS must be excluded first.
›Does diet affect PCOS?
Diet significantly affects PCOS severity by influencing insulin sensitivity and body weight. A lower glycemic index diet reduces fasting insulin and may restore more regular ovulation. A 2019 systematic review in Nutrients found that low-GI and Mediterranean dietary patterns produced statistically significant reductions in testosterone and fasting insulin compared with standard Western diets in women with PCOS.
›Can PCOS go away on its own?
PCOS does not resolve spontaneously in most cases, but its expression changes over a lifetime. Some women find that ovulatory cycles improve with weight loss or after pregnancy. The underlying predisposition to insulin resistance and androgen sensitivity persists, meaning ongoing monitoring of metabolic markers is appropriate even when symptoms quiet down.

References

  1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. https://pubmed.ncbi.nlm.nih.gov/37183590/
  2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800. https://pubmed.ncbi.nlm.nih.gov/11133067/
  3. American Diabetes Association Professional Practice Committee. Standards of care in diabetes 2023. Diabetes Care. 2023;46(Suppl 1):S19-S40. https://diabetesjournals.org/care/article/46/Supplement_1/S19/148058
  4. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010;203(3):201.e1-5. https://pubmed.ncbi.nlm.nih.gov/22419719/
  5. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592. https://pubmed.ncbi.nlm.nih.gov/23982515/
  6. Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999;13(6):946-957. https://pubmed.ncbi.nlm.nih.gov/9006589/
  7. Bhide P, Dilgil M, Gudi A, et al. Each small antral follicle in ovaries of women with polycystic ovary syndrome produces more antimullerian hormone than its counterpart in a normal ovary: an observational cross-sectional study. Fertil Steril. 2015;103(2):537-541. https://pubmed.ncbi.nlm.nih.gov/21436587/
  8. National Institutes of Health Evidence-based Methodology Workshop on PCOS. Final Report. December 2012. https://pubmed.ncbi.nlm.nih.gov/23636000/
  9. Day F, Karaderi T, Jones MR, et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet. 2018;14(12):e1007813. https://pubmed.ncbi.nlm.nih.gov/31043758/
  10. Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95(3):1048-1058.e2. https://pubmed.ncbi.nlm.nih.gov/21613304/
  11. Kandaraki E, Chatzigeorgiou A, Livadas S, et al. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab. 2011;96(3):E480-4. https://pubmed.ncbi.nlm.nih.gov/20538704/
  12. Rubin KH, Glintborg D, Nybo M, Abrahamsen B, Andersen M. Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(10):3848-3857. https://pubmed.ncbi.nlm.nih.gov/22933440/
  13. Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020;30(7):399-404. https://pubmed.ncbi.nlm.nih.gov/25677826/
  14. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012;27(5):1327-1331. https://pubmed.ncbi.nlm.nih.gov/24054527/
  15. Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32(5):1075-1091. https://pubmed.ncbi.nlm.nih.gov/29897462/
  16. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;(5):CD003053. https://pubmed.ncbi.nlm.nih.gov/22592695/
  17. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119-129. https://pubmed.ncbi.nlm.nih.gov/25006718/
  18. Jensterle M, Podbregar A, Goricar K, Gregoric N, Janez A. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect. 2022;11(3):e210496. [https://pubmed.ncbi.nlm.nih.gov/35229425/](https://pubmed.ncbi.